Impact of body mass index on clinicopathological outcome and biochemical recurrence after radical prostatectomy
Shintaro Narita(Akita University), Yoichi Arai(Japan Atomic Energy Agency), Norihiko Tsuchiya(Yamagata University), Yasuhiro Kaiho(Tohoku University), Takuya Koie(Hirosaki University), Narihiko Kakoi(Miyagi Prefectural Hospital Organization), Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Chikara Οhyama(Hirosaki University), Tohru Yoneyama(Hirosaki University), T Yamaguchi(Dokkyo University), Tomonori Habuchi(Akita University), Taro Tochigi(Miyagi Prefectural Hospital Organization), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization)
Cited by 15
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253